dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
dasatinib sandoz 70 mg
sandoz - københavn - dasatinib - tablett, filmdrasjert - 70 mg
dasatinib sandoz 20 mg
sandoz - københavn - dasatinib - tablett, filmdrasjert - 20 mg
dasatinib sandoz 50 mg
sandoz - københavn - dasatinib - tablett, filmdrasjert - 50 mg
dasatinib teva 70 mg
teva b.v. - dasatinibmonohydrat - tablett, filmdrasjert - 70 mg
dasatinib teva 20 mg
teva b.v. - dasatinibmonohydrat - tablett, filmdrasjert - 20 mg
dasatinib teva 50 mg
teva b.v. - dasatinibmonohydrat - tablett, filmdrasjert - 50 mg
methofill 10 mg
accord healthcare b.v. - metotreksat - injeksjonsvæske, oppløsning i ferdigfylt injektor - 10 mg
methofill 7.5 mg
accord healthcare b.v. - metotreksat - injeksjonsvæske, oppløsning i ferdigfylt injektor - 7.5 mg
methofill 12.5 mg
accord healthcare b.v. - metotreksat - injeksjonsvæske, oppløsning i ferdigfylt injektor - 12.5 mg